T. Rowe Price Associates
PCVX icon

T. Rowe Price Associates’s Vaxcyte PCVX Stock Holding History

T. Rowe Price Associates’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56.7M Sell
976,429
-198,910
-17% -$10.8M 0.01% 737
2025
Q4 		$54.2M Sell
1,175,339
-513,144
-30% -$23M 0.01% 794
2025
Q3 		$60.8M Sell
1,688,483
-1,481,764
-47% -$49.1M 0.01% 744
2025
Q2 		$103M Sell
3,170,247
-371,760
-10% -$12.2M 0.01% 564
2025
Q1 		$134M Sell
3,542,007
-424,949
-11% -$34M 0.02% 508
2024
Q4 		$325M Sell
3,966,956
-499,181
-11% -$49.6M 0.04% 335
2024
Q3 		$510M Buy
4,466,137
+1,292,970
+41% +$117M 0.06% 273
2024
Q2 		$240M Sell
3,173,167
-3,014
-0.1% -$205K 0.03% 390
2024
Q1 		$217M Buy
3,176,181
+498,359
+19% +$34.5M 0.03% 410
2023
Q4 		$168M Buy
2,677,822
+260,170
+11% +$13.5M 0.02% 440
2023
Q3 		$123M Buy
2,417,652
+225,270
+10% +$11.1M 0.02% 476
2023
Q2 		$109M Buy
2,192,382
+2,160,354
+6,745% +$102M 0.02% 507
2023
Q1 		$1.2M Buy
32,028
+1,760
+6% +$74.7K ﹤0.01% 1687
2022
Q4 		$1.45M Buy
30,268
+21,717
+254% +$852K ﹤0.01% 1592
2022
Q3 		$206K Sell
8,551
-5,377
-39% -$136K ﹤0.01% 2534
2022
Q2 		$303K Buy
13,928
+1,220
+10% +$28.2K ﹤0.01% 2436
2022
Q1 		$307K Buy
12,708
+1,127
+10% +$24.6K ﹤0.01% 2540
2021
Q4 		$276K Sell
11,581
-800
-6% -$18.6K ﹤0.01% 2627
2021
Q3 		$314K Buy
12,381
+2,042
+20% +$49.5K ﹤0.01% 2561
2021
Q2 		$233K Buy
+10,339
New +$212K ﹤0.01% 2669

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates's PCVX Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Vaxcyte (PCVX) stake by 17% in Q1 2026, selling an estimated $10.8M and leaving 976,429 shares worth $56.7M. The position accounts for 0.01% of the portfolio, ranked #737.

T. Rowe Price Associates first reported a position in PCVX in Q2 2021 and has held it in 20 quarters since. The position peaked at $510M in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • T. Rowe Price Associates held 976,429 shares of Vaxcyte worth $56.7M as of Q1 2026.
  • T. Rowe Price Associates sold 198,910 Vaxcyte shares in Q1 2026, an estimated $10.8M.
  • Vaxcyte made up 0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #737 holding.
  • T. Rowe Price Associates first reported a position in Vaxcyte in Q2 2021 and has held it in 20 quarters since.
  • T. Rowe Price Associates's Vaxcyte position peaked at $510M in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.